alpha-aminopyridine has been researched along with Prostatic Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadi, N; Butler, LM; Centenera, MM; Horvath, LG; Joshua, AM; Kench, J; Mahon, KL; Scheinberg, T; Sebastian, L; Stockler, M; Stricker, P; Thanigasalam, R; Woo, H | 1 |
| André, T; Bay, JO; Bouleuc, C; Hervé, L; Magné, N; Penel, N; Rodrigues, M; Sabatier, R; Thiery-Vuillemin, A; Wislez, M | 1 |
| Chen, S; Lin, D; Liu, Y; Peng, H; Wang, J; Wang, L; Wang, Y; Xiao, L; Xu, Y; Yang, K | 1 |
| Borre, M; Cieza-Borrella, C; Dagnaes-Hansen, F; Eeles, R; Haldrup, J; Hedensted, S; Jakobsson, ME; Kote-Jarai, Z; Norgaard, M; Olsen, JV; Riedel, M; Sorensen, KD; Strand, SH; Thomsen, M; Ulhoi, BP | 1 |
| Baird, AM; Bozkurt, E; Debelec Butuner, B; Finn, SP; Gray, SG; Kantarci, AG; Kotmakci, M; Oner, E | 1 |
| Abdel-Wahab, BA; Albarqi, HA; Ali, FEM; Hassanein, EHM; Walbi, IA | 1 |
| Huang, X; Li, M; Liao, W; Liu, B; Liu, J; Yin, Y; Zhu, R | 1 |
| Burton, EA; Chartier, S; Habets, G; Jimenez-Andrade, JM; Lin, PS; Mantyh, PW; Thompson, ML; Tsai, J; West, BL | 1 |
| Dai, Y; Siemann, DW | 2 |
| Fiedler, W; Schultze, A | 1 |
| Cooke, I; Goodchild, CS; Kolosov, A; Williams, ED | 1 |
| Gao, X; Jia, S; Lee, SH; Loda, M; Maira, SM; Roberts, TM; Signoretti, S; Stack, EC; Wu, X; Zhao, JJ | 1 |
| Agus, DB; Breslow, R; Butler, LM; Cordon-Cardo, C; Drobnjak, M; Higgins, B; Kutko, MC; LaQuaglia, MP; Marks, PA; Richon, VM; Rifkind, RA; Scher, HI; Tolentino, TR; Webb, Y | 1 |
2 review(s) available for alpha-aminopyridine and Prostatic Neoplasms
| Article | Year |
|---|---|
[2019 international oncology news: A compendium].
Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Digestive System Neoplasms; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Purines | 2020 |
Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Focal Adhesion Kinase 2; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hydroxamic Acids; Indoles; Male; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Pancreatic Neoplasms; Prostatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides | 2011 |
12 other study(ies) available for alpha-aminopyridine and Prostatic Neoplasms
| Article | Year |
|---|---|
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; E2F Transcription Factors; Humans; Kallikreins; Male; Neoadjuvant Therapy; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Purines; Randomized Controlled Trials as Topic; Research Design | 2020 |
PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target.
Topics: Aminopyridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cyclin E; Humans; Male; Membrane Proteins; Morpholines; Oncogene Proteins; Oxazines; Prognosis; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines | 2020 |
FRMD6 has tumor suppressor functions in prostate cancer.
Topics: Aged; Aminopyridines; Animals; Cell Proliferation; Cytoskeletal Proteins; DNA Methylation; Down-Regulation; Hippo Signaling Pathway; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Middle Aged; Prognosis; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Serine-Threonine Kinases; PTEN Phosphohydrolase; Tumor Suppressor Proteins | 2021 |
Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Topics: Aminopyridines; Cations; Cell Line, Tumor; Cell Survival; Gene Silencing; Histone Demethylases; Humans; Hydrazones; Lipids; Male; Nanoparticles; Particle Size; Prostate; Prostatic Neoplasms; Receptor, EphA2; RNA, Small Interfering; Transfection | 2021 |
Roflumilast protects from cisplatin-induced testicular toxicity in male rats and enhances its cytotoxicity in prostate cancer cell line. Role of NF-κB-p65, cAMP/PKA and Nrf2/HO-1, NQO1 signaling.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cisplatin; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Heme Oxygenase (Decyclizing); Male; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; NF-kappa B; Prostatic Neoplasms; Rats; Rats, Wistar; Signal Transduction | 2021 |
JIB‑04 induces cell apoptosis via activation of the p53/Bcl‑2/caspase pathway in MHCC97H and HepG2 cells.
Topics: Aminopyridines; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazones; Lung Neoplasms; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Suppressor Protein p53 | 2018 |
Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.
Topics: Aminopyridines; Analgesics; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Dogs; Formaldehyde; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinases; Pyrroles; Rats; Rats, Sprague-Dawley | 2015 |
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Topics: Aminopyridines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridones; Signal Transduction; Small Molecule Libraries | 2010 |
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Topics: Aminopyridines; Antibodies, Neutralizing; Autocrine Communication; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridones; RNA, Messenger; Signal Transduction | 2012 |
Flupirtine enhances the anti-hyperalgesic effects of morphine in a rat model of prostate bone metastasis.
Topics: Aminopyridines; Analgesics; Animals; Bone Neoplasms; Disease Models, Animal; Hyperalgesia; Male; Morphine; Pain; Prostatic Neoplasms; Rats; Rats, Wistar | 2012 |
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
Topics: Aminopyridines; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Castration; Imidazoles; Male; MAP Kinase Kinase Kinases; Mice; Mice, Transgenic; Morpholines; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Testosterone | 2013 |
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Topics: Acetylation; Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Line, Transformed; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Disease Models, Animal; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |